Sec. 3. (a) As used in this chapter, “biomarker” means a characteristic that is objectively measured and evaluated as an indicator of:

(1) normal biological processes;

(2) pathogenic processes; or

(3) pharmacologic responses to a specific therapeutic intervention, including known gene-drug interactions for medications being considered for use or already being administered.

     (b) The term includes gene mutations, characteristics of genes, and protein expression.

As added by P.L.37-2024, SEC.2.